Business Wire

CGTN: China Makes Proposals for UN's Role in Post-Pandemic Era

Share

The United Nations, beginning with 51 signatories at the end of World War II, has now grown to be a 193-nation body. As it celebrates its 75th founding anniversary, the organization and multilateralism it represents are facing unprecedented challenges with the rise of unilateralism and protectionism.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005948/en/

The challenges are being compounded by COVID-19, which has infected more than 31 million people and taken over 960,000 lives worldwide.

"What kind of UN does the world need and what role should it play in the post-pandemic era?"

Chinese President Xi Jinping raised the question and made proposals on Monday when addressing the high-level meeting to commemorate the 75th anniversary of the UN via video link.

The UN should uphold justice as countries, regardless of their sizes, are equal and should respect each other, Xi said, noting that this is a requirement of the progress of the times and the most important principle in the UN Charter.

The organization should be committed to achieving shared growth through consultation and collaboration, he stressed, calling on countries around the world to maintain common security and share the fruits of development.

Xi called for increased representation and a louder voice for developing countries in the UN and upholding the purposes and principles of the UN Charter.

He said the UN should promote international cooperation and lead efforts to solve various problems in the world. It should advance security, development and human rights in a balanced manner and give more emphasis to development on its global agenda, he added.

Uphold multilateralism, enhance cooperation

"During the 75 years of the UN, the world has seen rapid progress of the human society, profound changes in international situations and fast development of multilateralism," the Chinese president said.

He reiterated China's commitment to multilateralism and determination to safeguard the international system with the UN at its core.

As the international community strives to find solutions to problems faced by mankind, "multilateralism" has been a buzzword during the 75th session of the UN General Assembly that opened last week.

UN Secretary-General Antonio Guterres urged world leaders to work together at a time when there is a surplus of multilateral challenges and a deficit of solutions. "The future we want, the United Nations we need, is reaffirming our collective commitment to multilateralism is under way," he said.

Indeed, the need for more – and more effective – multilateralism is well known, he said, stressing that national sovereignty – a pillar of the Charter of the United Nations – goes hand‑in‑hand with enhanced international cooperation, based on common values and shared responsibilities for progress.

Russian Foreign Minister Sergei Lavrov said the international community is becoming increasingly fragmented, adding that "this is largely attributable to the fact that some countries are meddling in the domestic affairs of other states and imposing unilateral sanctions."

"The world is tired of dividing lines, of separating states into friends and foes, and demands stepping up all-encompassing and inclusive mutual assistance and cooperation," he said.

German Chancellor Angela Merkel said the interests of individual member states had "too often" forced the UN to lag behind its ideals.

"Those who believe that they can get along better alone are mistaken. Our well-being is something that we share – our suffering too. We are one world," she told the General Assembly.

While customs and cultures may differ, cooperation requires unstinting efforts to overcome misunderstanding, and beyond that, to embrace respect, European Council President Charles Michel noted.

"It is not our rhetoric that will matter," he said, but rather, the collective actions taken to foster a better world.

The theme of this year's UN high-level sessions is "The Future We Want, the UN We Need: Reaffirming Our Collective Commitment to Multilateralism." It echoes Xi's consistent call to build a community with a shared future for mankind.

Meanwhile, 48 former UN and government officials from around the world released an open letter – "A Time for Renewal: Calling for a Strengthened Multilateral System" – last Friday, expressing their hope that the UN would be transformed into a "stronger, more accountable, inclusive multilateral system."

"There is an urgent need for an explicit recognition by global leaders that we are at a turning point and must act decisively to defend and rejuvenate multilateralism," they said, stressing that recovery from the COVID-19 pandemic needs national leadership and effective global cooperation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye